Back to top
more

Novo Nordisk (NVO)

(Delayed Data from NYSE)

$111.94 USD

111.94
4,553,843

-0.01 (-0.01%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $111.97 +0.03 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

Novo Nordisk to Acquire Corvidia Therapeutics for $725M Cash

Novo Nordisk (NVO) enters into a deal to acquire Corvidia Therapeutics for an upfront payment of $725 million in cash.

Lilly Begins Cardiovascular Outcomes Study on Tirzepatide

Lilly (LLY) announces that the first patient dose has been delivered in a cardiovascular outcome study on its novel diabetes candidate, tirzepatide.

The Zacks Analyst Blog Highlights: Novo Nordisk, International Business Machines, Honeywell International, Amgen and S&P Global

The Zacks Analyst Blog Highlights: Novo Nordisk, International Business Machines, Honeywell International, Amgen and S&P Global

Sheraz Mian headshot

Top Stock Reports for Novo Nordisk, IBM & Honeywell

Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk (NVO), International Business Machines (IBM) and Honeywell International (HON).

Kinjel Shah headshot

Pharma Stock Roundup: Q1 Earnings of BMY, NVO, Coronavirus Update From PFE, RHHBY

Novo Nordisk (NVO) and Bristol-Myers (BMY) announce Q1 results. Pfizer (PFE), Roche (RHHBY) and Lilly (LLY) provide update on their coronavirus-related research efforts.

Novo Nordisk's (NVO) Q1 Earnings and Sales Beat Estimates

Novo Nordisk (NVO) beats on Q1 sales and earnings, and maintains outlook amid the coronavirus pandemic.

SNY vs. NVO: Which Stock Is the Better Value Option?

SNY vs. NVO: Which Stock Is the Better Value Option?

The Zacks Analyst Blog Highlights: Visa, Novo Nordisk, American Tower, Caterpillar and 3M

The Zacks Analyst Blog Highlights: Visa, Novo Nordisk, American Tower, Caterpillar and 3M

The Zacks Analyst Blog Highlights: Alibaba, Pfizer, S&P Global, Novo Nordisk and Duke Energy

The Zacks Analyst Blog Highlights: Alibaba, Pfizer, S&P Global, Novo Nordisk and Duke Energy

Mark Vickery headshot

Top Analyst Reports for Alibaba, Pfizer & S&P Global

Today's Research Daily features new research reports on 16 major stocks, including Alibaba Group (BABA), Pfizer (PFE) and S&P Global (SPGI).

Novo Nordisk's Rybelsus Gets EU Nod for Type II Diabetes

Novo Nordisk (NVO) gains the EU approval for Rybelsus to address adult patients with insufficiently-controlled type II diabetes for improving glycemic control as an adjunct to diet and exercise.

NVS vs. NVO: Which Stock Should Value Investors Buy Now?

NVS vs. NVO: Which Stock Is the Better Value Option?

The Zacks Analyst Blog Highlights: Alphabet, Procter & Gamble, Philip Morris, Novo Nordisk and Tesla

The Zacks Analyst Blog Highlights: Alphabet, Procter & Gamble, Philip Morris, Novo Nordisk and Tesla

Mark Vickery headshot

Top Analyst Reports for Alphabet, Procter & Gamble & Philip Morris

Today's Research Daily features new research reports on 16 major stocks, including Alphabet (GOOGL), Procter & Gamble (PG) and Philip Morris International (PM).

Lilly Gets CRL for Jardiance in Type I Diabetes Indication

Lilly's (LLY) label expansion application seeking approval of its type II diabetes medicine as a treatment for type I diabetes fails to get approval from the FDA.

The Zacks Analyst Blog Highlights: Microsoft, salesforce.com, Novo Nordisk, American Express and Fiserv

The Zacks Analyst Blog Highlights: Microsoft, salesforce.com, Novo Nordisk, American Express and Fiserv

Kinjel Shah headshot

Pharma Stock Roundup: SNY, RHHBY, PFE's Coronavirus Product Development & Other Updates

Pfizer (PFE) is set to jointly develop BioNTech's potential coronavirus vaccine. Regeneron/Sanofi (SNY) and Roche will study their RA drugs, Kevzara & Actemra, respectively to treat severe COVID-19 infection.

Mark Vickery headshot

Top Analyst Reports for Microsoft, salesforce.com & Novo Nordisk

Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), salesforce.com (CRM) and Novo Nordisk (NVO).

Sweta Killa headshot

Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?

Sector ETF report for PPH

Kinjel Shah headshot

Pharma Stock Roundup: BMY, GSK, SNY Q4 Results, MRK Earnings & Split

Merck (MRK), Bristol Myers (BMY), Sanofi (SNY), Glaxo (GSK) and Novo Nordisk (NVO) announce Q4 results.

Novo Nordisk (NVO) Q4 Earnings Match Estimates, Revenues Beat

Novo Nordisk (NVO) posts in-line earnings, while revenues beat estimates in the fourth quarter of 2019.

SNY vs. NVO: Which Stock Should Value Investors Buy Now?

SNY vs. NVO: Which Stock Is the Better Value Option?

Novo Nordisk's Ozempic Gets FDA Nod for CV Risk Reduction

Novo Nordisk's (NVO) Ozempic gets FDA approval for reducing the risk of major adverse cardiovascular events in people with type II diabetes and established CVD.

Lilly to Launch Cheaper Versions of Humalog KwikPen Insulins

Eli Lilly (LLY) announced plans to launch cheaper version of its Humalog insulins, Mix75/25 KwikPen and Junior KwikPen.

Novo Nordisk's Shares Up in a Year on Pipeline Progress

Novo Nordisk's (NVO) shares have gained in the past year as it makes significant progress in pipeline development.